Next-generation Sequencing (NGS) Market

Illumina (US) and Thermo Fisher Scientific (US) are Leading Players in the Next-generation Sequencing (NGS) Market

The next-generation sequencing market is projected to reach USD 24.2 billion by 2026 from USD 10.3 billion in 2021, at a CAGR of 18.7 % during the forecast period. The growth of this market is mainly driven by advancements in NGS platforms, declining costs of genome sequencing, and improving regulatory and reimbursement scenario for NGS-based diagnostic tests.

The prominent players operating in the next-generation sequencing market are Illumina (US), Thermo Fisher Scientific (US), BGI Group (China), PerkinElmer (US), and Agilent Technologies (US).

To know about the assumptions considered for the study download the pdf brochure

Illumina (US) is the leading player in the NGS market. This is attributed to its robust product offerings and NGS services. The company’s product segment includes a wide range of sequencing, genotyping, gene expression, and molecular diagnostic platforms, consumables, and services that run on the SBS technology. In the past three years, Illumina has launched several products in the market, including the NovaSeqT 6000 v1.5 Reagent Kit, TruSight Software Suite, NextSeq 1000, NextSeq 2000, and VeriSeq NIPT Solution v2. In order to ensure continuous product development, the company invests a significant amount of its revenue on R&D expenditure.

Thermo Fisher Scientific (US) held the second position in the next-generation sequencing market in 2020. The company’s NGS sequencers run on ion semiconductor sequencing technology. Thermo Fisher will continue to have a strong market position owing to its robust platforms and consumables. The company also has a significant geographic presence. The company adopts organic and inorganic strategies such as acquisitions, product launches, and expansions to strengthen its market position. For instance, in August 2020, Thermo Fisher Scientific launched hematology-oncology assays for the Ion Torrent Genexus System, which enables simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day.

Related Reports:

Next-generation Sequencing (NGS) Market by Product & Service (Consumables, Platforms, Services, Bioinformatics), Technology (SBS, SMRT), Application (Diagnostic, Drug Discovery, Agriculture), End User (Pharma, Biotech, Academic) - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 2697
RI Published ON
4/20/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Next-generation Sequencing (NGS) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved